ArticleiScience2024

Leveraging Vγ9Vδ2 T cells against prostate cancer through a VHH-based PSMA-Vδ2 bispecific T cell engager.

Lisa A King et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.